Systematic Review

Cystic Fibrosis in the SARS-CoV-2/COVID-19 Pandemic

Hannah R. Mathew; May Y. Choi; Michael D. Parkins; Marvin J. Fritzler

Disclosures

BMC Pulm Med. 2021;21(173) 

In This Article

Methods

A literature search was conducted using EMBASE and MEDLINE between April 28 and December 10, 2020 (Figure 1). The objective of the search was to identify studies that described COVID-19 disease outcomes in the population that contracted the virus, with exposure constituting a history of CF. The primary exclusion criteria consisted of singular case reports, absences of patient descriptions, and study of non-health-related outcomes. Both primary and secondary literature were included. Key search terms included "cystic fibrosis," "coronavirus," "SARS," "SARS-CoV-2," and "COVID-19" (see Table 1 for MEDLINE search strategy; see Table 5 for EMBASE search strategy). Each of the included studies was summarized (see Table 2) and evaluated using the Newcastle–Ottawa Quality Assessment Scale to examine risk of bias (see Table 3). Furthermore, information collected and reported by the European Cystic Fibrosis Society Patient Registry (ECFSPR) until April 16, 2021 on SARS-CoV-2 infection in CF was also included as a supplement to the extracted studies.

Figure 1.

PRISMA flow diagram of literature identification, screening, assessment, and inclusion (http://prisma-statement.org/prismastatement/flowdiagram)

processing....